AAV-SDHD

AAV-SDHD is an investigational adeno-associated virus (AAV)-based gene therapy designed to deliver the gene encoding succinate dehydrogenase complex subunit D (SDHD) to hepatocytes. Developed by the Institute of Biomedicine of Seville (IBiS) in collaboration with the Spanish National Research Council (CSIC), the University of Seville, and the Virgen del Rocio University Hospital, AAV-SDHD aims to restore succinate dehydrogenase (SDH) enzymatic activity, which is typically impaired in metabolic dysfunction-associated steatotic liver disease (MASLD). In preclinical mouse models of MASLD, intravenous administration of AAV-SDHD successfully restored SDH activity, reduced hepatic steatosis, and alleviated liver inflammation, highlighting its potential as a therapeutic strategy for MASLD and its progression to steatohepatitis and fibrosis.

Other names

AAV encoding SDHDadeno-associated virus encoding SDHDadeno-associated virus encoding succinate dehydrogenase subunit DrAAV-SDHD